Source: Labyrinth One Leads CTC Technology, Debuting at AACR 2026
The BloodScan team will participate in one of the world's most prominent cancer research events, AACR Annual Meeting 2026, from April 19-22, 2026, to engage with leading research institutions, clinical experts, and biotech companies from around the globe to discuss the latest advancements in cancer research and translational medicine.
At this exhibition, BloodScan will showcase its core technology, "Labyrinth One - Automated Circulating Tumor Cell (CTC) Enrichment System," dedicated to providing high-efficiency, high-recovery, and cell-viable CTC enrichment solutions, assisting researchers and clinical teams in accelerating early cancer detection and the development of precision medicine.
Based on microfluidic architecture, Labyrinth One optimizes the cell separation process to improve detection efficiency while maintaining cellular integrity. It is suitable for research applications across various cancer types, including pan-cancer detection for head and neck cancer, breast cancer, lung cancer, pancreatic cancer, and more.
We cordially invite global partners, researchers, and industry leaders to visit our booth to exchange ideas and gain deeper insights into how BloodScan is driving the next phase of development in the liquid biopsy field through innovative technology.
Exhibition Information
Event Name: AACR Annual Meeting 2026
Date: April 19-22, 2026
Location: San Diego, USA
Booth Information: # 1756 (Ground Level)